MASTERINVEST Kapitalanlage GmbH Boosts Stock Holdings in CVS Health Corporation $CVS

MASTERINVEST Kapitalanlage GmbH grew its position in CVS Health Corporation (NYSE:CVS) by 99.8% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 16,211 shares of the pharmacy operator’s stock after acquiring an additional 8,098 shares during the quarter. MASTERINVEST Kapitalanlage GmbH’s holdings in CVS Health were worth $1,164,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in CVS. Swiss RE Ltd. acquired a new stake in CVS Health during the 4th quarter worth $26,000. Sankala Group LLC acquired a new stake in shares of CVS Health in the fourth quarter valued at about $28,000. Caitong International Asset Management Co. Ltd lifted its stake in shares of CVS Health by 407.2% in the third quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock worth $26,000 after buying an additional 281 shares in the last quarter. Mcguire Capital Advisors Inc. acquired a new position in CVS Health during the fourth quarter worth about $28,000. Finally, Ares Financial Consulting LLC purchased a new position in CVS Health in the 4th quarter worth approximately $29,000. 80.66% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Truist Financial raised its price target on CVS to $118 and reiterated a buy rating, reinforcing bullish analyst sentiment and suggesting additional upside from current levels.
• Positive Sentiment: CVS Caremark reached a global settlement with the FTC that CVS says advances transparency and affordability in prescription drug pricing, potentially easing a major legal overhang for the pharmacy-benefit manager business. Article Title
• Positive Sentiment: Reports highlighting CVS as a 52-week high stock and a potentially attractive long-term value play are keeping momentum traders and value investors interested.
• Neutral Sentiment: CVS continued to promote Aetna provider survey results showing improved payer trust and the benefits of digital tools, which is supportive for the healthcare-services narrative but not a major immediate stock catalyst. Article Title
• Neutral Sentiment: CVS also affirmed its dividend and expanded GLP-1 support programs, which helps the investment case, though the market may still be waiting to see whether those efforts meaningfully improve employer economics and utilization trends.
• Negative Sentiment: Wall Street Zen downgraded CVS to Hold, and the stock is trading near its recent high, which could prompt some investors to question near-term valuation after a strong run.

Insider Buying and Selling

In other news, Director Larry Robbins sold 370,462 shares of the business’s stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $93.45, for a total value of $34,619,673.90. Following the sale, the director directly owned 4,824,799 shares of the company’s stock, valued at approximately $450,877,466.55. The trade was a 7.13% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Tilak Mandadi sold 69,551 shares of the stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the transaction, the executive vice president directly owned 10,133 shares of the company’s stock, valued at $907,714.14. The trade was a 87.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 3,441,551 shares of company stock worth $323,703,977 over the last three months. Insiders own 0.85% of the company’s stock.

CVS Health Trading Down 0.2%

Shares of CVS Health stock opened at $106.01 on Thursday. The stock has a 50 day moving average of $98.25 and a 200 day moving average of $84.79. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.66 and a current ratio of 0.87. The firm has a market capitalization of $135.26 billion, a price-to-earnings ratio of 46.70, a PEG ratio of 1.04 and a beta of 0.61. CVS Health Corporation has a fifty-two week low of $58.50 and a fifty-two week high of $107.94.

CVS Health (NYSE:CVS) last announced its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, beating the consensus estimate of $2.21 by $0.36. The business had revenue of $100.43 billion for the quarter, compared to analyst estimates of $94.99 billion. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The company’s quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.25 EPS. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, research analysts predict that CVS Health Corporation will post 7.46 earnings per share for the current year.

CVS Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 23rd will be given a dividend of $0.665 per share. The ex-dividend date is Thursday, July 23rd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.5%. CVS Health’s dividend payout ratio (DPR) is currently 117.18%.

Analyst Ratings Changes

CVS has been the subject of a number of analyst reports. Piper Sandler restated an “overweight” rating and issued a $113.00 price target on shares of CVS Health in a research report on Monday, June 1st. UBS Group lifted their price objective on CVS Health from $100.00 to $115.00 and gave the stock a “buy” rating in a research report on Monday, June 8th. DA Davidson upped their target price on CVS Health from $80.00 to $100.00 and gave the company a “buy” rating in a report on Thursday, May 7th. JPMorgan Chase & Co. raised their target price on CVS Health from $101.00 to $111.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 12th. Finally, Wells Fargo & Company boosted their price target on shares of CVS Health from $103.00 to $123.00 and gave the company an “overweight” rating in a research report on Monday. Twenty-one equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $105.38.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.